Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) - Overview
Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) - Companies Involved in Therapeutics Development
AL-S Pharma AG
Alexion Pharmaceuticals Inc
Alnylam Pharmaceuticals Inc
Apic Bio Inc
AveXis Inc
Biogen Inc
Collaborative Medicil Development LLC
Priavoid GmbH
Thera Neuropharma Inc
Trucode Gene Repair Inc
Voyager Therapeutics Inc
Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) - Drug Profiles
Antisense Ri Oligonucleotides to Inhibit Superoxide Dismutase for CNS Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AP-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
APB-102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AVXS-301 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclol Antibody to Inhibit SOD1 for Amyotropic Lateral Sclerosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Oligonucleotides to Activate SOD1 for Amyotropic Lateral Sclerosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Ri Gene Therapy to Inhibit SOD1 for Amyotrophic Lateral Sclerosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Activate SOD-1 for Amyotrophic Lateral Sclerosis and Parkinson’s Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Superoxide Dismutase 1 for Amyotrophic Lateral Sclerosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to Inhibit SOD1 for Amyotrophic Lateral Sclerosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TDI-186 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
THN-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tiomolibdate choline - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tofersen sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VYSOD-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VYSOD-102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) - Dormant Products
Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) - Product Development Milestones
Featured News & Press Releases
Oct 16, 2019: Neurimmune and TVM Capital Life Science announce the initiation of AL-S Pharma’s phase 1 study of AP-101 for the treatment of ALS
Oct 14, 2019: Collaborative Medicil Development enrolls first patient in a randomized, placebo-controlled clinical trial of CuATSM for The treatment of Amyotrophic Lateral Sclerosis
Jul 22, 2019: Apic Bio’s APB-102 receives Orphan Drug Desigtion from the FDA for the treatment of genetic SOD1 ALS
Jul 01, 2019: Copper compound shows further potential as therapy for slowing ALS
Jun 10, 2019: Collaborative Medicil Development reports that lead drug shows dose-dependent improvement in Parkinson’s disease
May 03, 2019: Biogen reports positive data from Phase I/II study of tofersen
May 02, 2019: Experimental drug shows promise for genetic form of ALS
Apr 29, 2019: Voyager Therapeutics Announces New Data on VY-SOD102 at the American Society of Gene and Cell Therapy 2019 Annual Meeting
Apr 17, 2019: Collaborative Medicil Development wins AU$1 million grant award from FightMND
Jan 14, 2019: Researchers report positive results from motor neurone disease trial
Jan 07, 2019: Collaborative Medicil Development reports that lead drug modifies ALS progression
Dec 17, 2018: Biogen provides update on SOD1 phase I Antisense trial
Oct 16, 2018: Voyager Therapeutics announces preclinical data for Amyotrophic Lateral Sclerosis at the Congress of the European Society of Gene and Cell Therapy
Jul 25, 2018: Next-generation ALS drug silences inherited form of the disease in animal models
Jul 16, 2018: Washington University’s new ALS therapy in clinical trial stage
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Top 10 Indications, H1 2020
Number of Products by Mechanism of Actions, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020


List of Tables


Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indication, H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Number of Products under Investigation by Universities/Institutes, H1 2020
Products under Investigation by Universities/Institutes, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by AL-S Pharma AG, H1 2020
Pipeline by Alexion Pharmaceuticals Inc, H1 2020
Pipeline by Alnylam Pharmaceuticals Inc, H1 2020
Pipeline by Apic Bio Inc, H1 2020
Pipeline by AveXis Inc, H1 2020
Pipeline by Biogen Inc, H1 2020
Pipeline by Collaborative Medicinal Development LLC, H1 2020
Pipeline by Priavoid GmbH, H1 2020
Pipeline by Thera Neuropharma Inc, H1 2020
Pipeline by Trucode Gene Repair Inc, H1 2020
Pipeline by Voyager Therapeutics Inc, H1 2020
Dormant Projects, H1 2020